Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Friday November 13, 2009

DrStockPick.com Stock Report!

CEPH, PWRM

**************************************************************

CEPH, Cephalon Inc.

CEPH engages in the discovery, development, and commercialization of products for central nervous system, inflammatory disease, pain, and oncology therapeutic areas.

According to a Securities and Exchange Commission filing yesterday, CEPH will give Barr Pharmaceuticals Inc. (which now is part of Israel-based Teva Pharmaceutical Industries) a license to sell a generic version of the pain drug Fentora in 2018 as part of a patent lawsuit settlement.

More about CEPH at www.cephalon.com

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

PWRM is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer

...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Wednesday November 4, 2009

DrStockPick.com Stock Report!

**************************************************************

Consorteum Holdings Inc. (OTCBB: CSRH) announced that it has proceeded to launch its consumer stored value rebate card. The consumer rebate card program will offer manufacturers and retailers a new way to process mail-in rebates that ensures increased customer loyalty and decreased overhead costs. Consorteum will work directly with manufactures and retailers to reduce the administration costs associated with mail-in rebate programs while providing a new way to increase consumer awareness. Additional revenue and cost-saving opportunities will be

...

Highlights include Alkermes Inc. (ALKS), Johnson & Johnson (JNJ), Eli Lilly & Co. (LLY) and Cephalon Inc. (CEPH).Fiscal 4th quarter 2009 financial performance lackluster; guidance for fiscal 2010 way below expectationsAlkermes Inc. (ALKS) reported fiscal fourth quarter (ended March 31, 2009) financial results on May 21, 2009.Total revenues for the quarter ended March 31, 2009 were $43.9 million, down 30% compared to $62.4 million for the same period in 2008.Manufacturing revenues for the quarter were $24.7 million compared to $31.8 million for the same period in 2008, a decrease of 28.7% year over year.Vivitrol sales were $4.5 million in fiscal fourth quarter 2009, compared to $4.3 million from fiscal fourth quarter 2008. Alkermes began to record product sales (Vivitrol) as part of its total revenue in fiscal fourth quarter of 2009 ended March 31, 2009 ...

Cephalon Inc. (CEPH) rose slightly in morning trade to pressure a short-term level of resistance at $65.97. The average forecast on the company's full-year earnings has gone up by 4 cents to $5.88 in the last week. Cephalon is a Zacks#2 Rank ("Buy") stock.

"CEPH" Free Stock Analysis: Buy? Sell? Hold?Zacks Investment Research

As M&A activity peppers the Healthcare industry, prudent investors are searching for the next big acquisitions. 2008 left I-banks hanging their heads as weak market conditions and restricted lending created a stale environment for M&A activity. However, the dire need for drug companies to protect their future sales brings out the big players in the industry looking to strengthen their pipelines and diversify products to ease investors’ fears over the $160 billion in revenues of drugs coming off patent protection by 2016.  Investors looking for M&A may want to keep their eye on these two attractive companies.

Cephalon, Inc. [CEPH: 66.31, -0.70 (-1.04%)]

Cephalon, Inc is a bio-pharmaceutical company that focuses on developing and selling drugs pertaining to central nervous system disorders, oncology, pain, and addiction.  CEPH’s most bankable drug, Provigil, accumulated about $1 billion in revenue in 2008.  Provigil is approved for the treatment of narcolepsy, shift work

...

Highlighted stocks include: Alcoa Inc. (...

Acusphere, Inc. (ACUS) recently signed a definitive agreement with Cephalon, Inc. (CEPH) whereby Acusphere raised $20M in cash ($5M upfront and $15M in a senior secured convertible loan). In return for their money, Cephalon has licensed AI-525, a preclinical injectable celecoxib for post-op pain and the right to potentially license Imagify, a billion-dollar product for the detection of coronary artery disease.We are very pleased with the deal, especially in this environment. We regard it as a testament to the potential of Imagify. With the cash position now secure, all eyes turn to the FDA’s cardio-renal advisory panel meeting in December 2008. A positive review at that time should send the shares significantly higher.We also note that should Cephalon decide to license Imagify, Acusphere was able to maintain a significant portion of the economics. The deal entitles Acusphere to a sizable approval milestone of …

Adolor Corporation (Nasdaq GM:ADLR), a biopharmaceutical company focused on the development of products related to pain management, today appointed John M. Limongelli, Esq., as general counsel, managing all legal affairs for the company. Mr. Limongelli will also be a senior vice president, reporting directly to Adolor president and CEO Michael Dougherty.

Mr. Limongelli comes from a much larger corporate environment, Cephalon, Inc., a global pharmaceutical company with annual sales approaching $2 billion, where he was associate general counsel and vice president. Prior to that he was with one of the world’s largest law firms, Morgan, Lewis & Bockius out of Philadelphia, and is a graduate of Temple University.

“As Adolor continues its transition to a commercial stage pharmaceutical company, John’s industry and private practice experience will prove to be an invaluable asset to the company” said Dougherty.

Adolor (www.Adalor.com) was founded in 1993. Located just outside of Philadelphia, it has

...